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The objective of this study was to examine whether the PI3-kinase/Akt pathway is involved in the ac-
tivation of endothelial nitric oxide synthase (eNOS) and in the subsequent increase of nitric oxide (NO)
production that has been proved to play a role in the antiarrhythmic effect of acute simvastatin treatment
in anaesthetised dogs, subjected to a 25 min occlusion and reperfusion of the left anterior descending
coronary artery. Using the same model, 12 dogs out of the 26 controls (given the solvent of simvastatin)
and 11 dogs out of the 23 animals treated with intracoronary administered simvastatin (0.1 mg/kg), were
now received wortmannin (1.5 mg/kg, ic.), a selective inhibitor of PI3-kinase. In another 13 dogs the
effects of DMSO (0.1%), the vehicle of wortmannin, were examined. Compared to the controls, simvas-
tatin markedly reduced the severity of ischaemia (epicardial ST-segment, inhomogeneity) and ven-
tricular arrhythmias that were reversed (except the occlusion-induced ventricular ﬁbrillation [VF; 50%,
0%, 0%]) by the administration of wortmannin. Thus in these groups there were 310745, 62714,
307759 ectopic beats, 7.171.4, 0.37 0.2, 4.371.3 tachycardiac episodes that occurred 93%, 17% and
73% of the dogs during occlusion, whereas survival following reperfusion was 0%, 67% and 0%, respec-
tively. Simvastatin also increased the phosphorylation of eNOS and the plasma nitrate/nitrite levels, but
reduced myocardial superoxide production on reperfusion. These effects of simvastatin were also abol-
ished in the presence of wortmannin. We conclude that the NO-dependent antiarrhythmic effect of
simvastatin involves the rapid activation of eNOS through the stimulation of the PI3-kinase/Akt pathway.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
There is substantial evidence that chronic statin treatment has
many salutary effects, among which the most important one is,
perhaps, a reduction in mortality due to sudden cardiac death (e.g.
Lipid Study Group, 1998; Gould et al., 2007; Sever et al., 2008). It
has been proposed that these beneﬁcial cardioprotective effects, at
least in part, are independent from the lipid lowering effects of
statins, since the protection is apparent even under normocho-
lesterolemic conditions (e.g. LIPID Study Group, 1998; Lefer et al.,
2001; Chen et al., 2003). Although the precise mechanism through
which statins yield cardioprotection is still not well established,
clinical and experimental studies suggest that nitric oxide (NO),
generated via the activation of endothelial nitric oxide synthase
(eNOS), may play a mediator role (Altun et al., 2014; Athyros et al.,and Pharmacotherapy, Uni-
dicine, Dóm tér 12, P.O. Box
Végh).2014; Wang et al., 2014). The mechanisms by which statins may
activate eNOS are even less understood; the prevention of the
oxLDL-mediated down-regulation of eNOS mRNA and protein le-
vels (Hernández-Perera et al., 1998), as well as the up-regulation of
eNOS by blocking the synthesis of those isoprenoid intermediates
of the cholesterol synthesis pathway that are involved in the post-
translational modiﬁcation of proteins which regulate eNOS ex-
pression (Laufs et al., 1997; Laufs and Liao, 1998), were suggested
as potential mechanisms for eNOS activation during chronic statin
administration.
More recent studies emphasise that the acute administration of
statins may also provide cardioprotection. The ﬁrst evidence for
this resulted from the study of Wolfrum et al. (2004), showing that
in anaesthetised rats subjected to coronary artery occlusion, sim-
vastatin administration just prior to reperfusion, markedly re-
duced infarct size, increased PI 3-kinase activity, as well as
AktSer473 and eNOSSer1177 phosphorylation (Wolfrum et al., 2004).
Similarly, we showed in anaesthetised dogs that a single dose of
simvastatin, given prior to a 25 min coronary artery occlusion,
signiﬁcantly reduced the severity of the occlusion-induced
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ischaemia and reperfusion insult (Kisvári et al., 2014). This marked
antiarrhythmic effect of simvastatin was associated with increased
eNOS activity and NO production, since the protection, except that
against the occlusion-induced ventricular ﬁbrillation, was abol-
ished by the administration of the NOS inhibitor L-NAME (Kisvári
et al., 2014).
Following this line of reasoning, in this study we aimed to in-
vestigate the NO-dependent antiarrhythmic effect of acute sim-
vastatin administration, primary focusing on those signalling
pathways that may result in rapid activation of eNOS. One such a
pathway, which has been proposed to activate eNOS through
phosphorylation within minutes, would be the PI 3-kinase/Akt
signalisation (Laufs and Liao, 1998). There already have evidence
that following acute simvastatin administration the activation of
the PI 3-kinase/Akt/eNOS cascade is involved in the increase of NO
synthesis in endothelial cells (Kureishi et al., 2000), and in the
reduction of infarct size (Wolfrum et al., 2004). Since there is a lack
of information that the pronounced antiarrhythmic effect of a
single dose of simvastatin attains also through the stimulation of
the PI 3-kinase/Akt/eNOS, we have designed studies to examine
this, using the PI 3-kinase inhibitor wortmannin in our canine
model of ischaemia and reperfusion.2. Materials and methods
2.1. Ethics statement
The origin and upkeep of the dogs used in our experiments
were in accord with Hungarian law (XXVIII, chapter IV, paragraph
31) regarding the use of large experimental animals, which con-
forms to the Guide for the Care and Use of Laboratory Animals
(ILAR, 1996), and also conformed to Directive 2010/63/EU of the
European Parliament. The protocols were approved by the Ethical
Committee for the Protection of Animals in Research of the Uni-
versity of Szeged, Szeged, Hungary (approval number: I-74-5-
2012) and by the Department of Animal Health and Food Control
of the Ministry of Agriculture and Rural Development (authority
approval number XIII/1211/2012).
2.2. Animals and surgical preparation
Inbred mongrel dogs of both sexes with a mean body weight of
2272 kg were used. Before the experiments, the dogs were
housed in an animal room (temperature 20 °C; humidity from 40%
to 70%; lighting 12 h per day; two animals per pen) for at least two
weeks and fed a standard diet with ad libitum access to water.
Food was withdrawn 24 h before anaesthesia. The surgical pro-
cedures were similar to those described previously (Kisvári et al.,
2014). In brief, the dogs were lightly anaesthetised with sodium
pentobarbitone (30 mg/kg i.v.; Sigma, St. Louis, MO, USA) and the
right femoral vein was prepared and catherised for the adminis-
tration of further anaesthetic (mixture of chloralose and urethane,
60 and 200 mg/kg, respectively; Sigma, St. Louis, MO, USA) to
maintain anaesthesia. The depth of anaesthesia was monitored by
the examination of the cornea and pain reﬂexes, as well as by
measuring the blood pressure. The animals were then intubated,
and ventilated with room air using a Harvard respirator (Harvard
Apparatus, Natick, MA, USA) at a rate and volume sufﬁcient to
maintain arterial blood gases and pH within physiological limits
(Végh et al., 1992a). Body temperature was measured from the
mid-oesophagus, and maintained by a heating pad at 3770.5 °C.
A polyethylene catheter was inserted into the right femoral
artery to measure arterial blood pressure (systolic and diastolic). A
Millar tip catheter (5F, Millar Instruments, USA) was introduced,via the left carotid artery, into the left ventricle (LV) to detect
changes in systolic (LVSP) and end-diastolic (LVEDP) pressures as
well as in LVdP/dt.
A thoracotomy was performed at the ﬁfth intercostal space and
the anterior descending branch of the left coronary artery (LAD)
was prepared for occlusion just proximal to the ﬁrst main diagonal
branch. Distal to the occlusion site a smaller side branch of the
same artery was also prepared and cannulated for the local ad-
ministration of drugs (simvastatin and wortmannin) and vehicles
(solvent of simvastatin and DMSO). Another catheter was posi-
tioned through the right jugular vein into the coronary sinus to
obtain blood samples for the assessment of plasma nitrate/nitrite
(NOx) levels. In some dogs from each group, the left circumﬂex
(LCX) coronary artery was also prepared to measure coronary
blood ﬂow (CBF; ml/min) by means of a transit time Doppler ﬂow
probe (Hugo Sachs Electronics, Germany).
The severity of myocardial ischaemia was evaluated by the
measurement of changes in the epicardial ST-segment and in the
degree of inhomogeneity of electrical activation, using a composite
electrode positioned within the potentially ischaemic area as
previously described (Végh et al., 1992a; Kisvári et al., 2014). In-
homogeneity was assessed as the greatest delay in activation fol-
lowing coronary artery occlusion, and it was expressed in milli-
seconds. The composite electrode also contains four unipolar
electrodes by which changes in epicardial ST-segment were
detected.
Ventricular arrhythmias were assessed according to the Lam-
beth conventions (Walker et al., 1988) with that modiﬁcation as
outlined previously (Végh et al., 1992a). In brief, the total number
of ventricular premature beats (VPBs), the incidence and the
number of episodes of ventricular tachycardia (VT; deﬁned as a
run of four or more consecutive VPBs at a rate faster than the
resting heart rate), and the incidence of ventricular ﬁbrillation (VF)
were assessed during the occlusion period. During reperfusion,
only the incidence of VF, which is a fatal event in this species, was
determined. Dogs that were alive 1–2 min after reperfusion were
considered to be survivors.
All parameters, together with a chest lead electrocardiogram,
were measured with a Plugsys Haemodynamic Apparatus (Hugo
Sachs Electronics, Germany) and recorded on a Graphtec Thermal
Array Recorder (Hugo Sachs Electronics, Germany). From the chest
lead electrocardiogram the heart rate (HR), the number and in-
cidence of arrhythmias and the QT interval were determined. The
QTc was calculated using the Bazett's formula.
2.3. Measurement of plasma nitrate/nitrite (NOx) levels
Plasma nitrate/nitrite (NOx) concentrations were determined
by means of the Griess reaction in blood samples taken from the
coronary sinus at various time intervals (Fig. 1) as described pre-
viously (Kiss et al., 2010; Kisvári et al., 2014). After preparation of
blood samples, the absorbance of the azo compound was mea-
sured spectrophotometrically at a wavelength of 540 nm and the
total nitrate/nitrite (NOx) concentration (mmol/l) was determined
using a standard calibration curve of NaNO2 and NaNO3 (Sigma, St
Louis, MO, USA).
2.4. Determination of eNOS phosphorylation by Western blot
The total and the phosphorylated forms of eNOS were de-
termined in myocardial samples taken from the left ventricular
wall, supplied by the LAD, using the same method described
previously (Gönczi et al., 2012; Kovács et al., 2013; Kisvári et al.,
2014). After preparation of protein extracts (100 μg) the blots were
immunolabeled with a polyclonal rabbit antibody for eNOS and a
monoclonal mouse anti-eNOS as primary antibody for peNOS
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Fig. 1. Experimental protocol. Five groups of dogs were used. After a 20 min period of recovery, control dogs (n¼14) were received the solvent of simvastatin in slow (over
5 min) intracoronary (ic.) bolus injection just prior to a 25 min occlusion of the left anterior descending (LAD) coronary artery. In 23 dogs activated simvastatin was
administered in a dose of 0.1 mg/kg by the same route. In 11 out of these 23 animals the PI 3-kinase inhibitor wortmannin (1.5 mg/kg, ic.) was also administered 15 min
before the simvastatin treatment. In two other groups wortmannin (n¼12) and dimethylsulphoxide (DMSO; n¼13), the vehicle of wortmannin were given. All these dogs
then underwent a 25 min LAD occlusion with or without (n¼5 or 6 dogs in each group) subjecting them to reperfusion. During the experiments blood samples (BS) were
taken at various time intervals (indicated by arrows) from the coronary sinus to determine plasma nitrite/nitrate (NOx) levels. Myocardial tissue samples (TS) were also
collected at the end of the ischaemic period or 5 min after reperfusion for further biochemical analyses.
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1:2500, with an HRP-conjugated anti-rabbit and anti-mouse as
secondary antibodies, respectively (Dako, Danmark) in a dilution
of 1:8000. Band densities were detected with the ECL Plus kit (GE
Healthcare, Buckinghamshire, UK) and developed on Amersham
Hyperﬁlm™ (GE Healthcare, Buckinghamshire, UK). Pixel in-
tensities of each band were measured using ImageJ software (NIH).
Three parallel Western blots were performed for the statistical
analysis using Bonferroni correction. On the blots each examined
group was compared to the sham-controls. For the veriﬁcation of
equal loading, PVDF membranes were labelled with Coomassie
Blue.
An integrated optical density value (the sum of each pixel value
corrected to the background) was formed by drawing equal size
boxes around the bands. The intensities obtained from both the
total and peNOS bands were normalised to this integrated value.1 Data obtained from 8 dogs in the control and from 6 dogs in the simvastatin
groups were already used in Kisvári et al. (2014).2.5. Assessment of the generation of reactive oxygen species
The production of reactive oxygen species (ROS) occurring
during reperfusion was determined by dihydroethidium (DHE;
Sigma-Aldrich) ﬂuorescence staining as described previously (Kiss
et al., 2010, Kisvári et al., 2014). Cryosections (20 mm) were pro-
duced from tissue blocks (excised from the ischaemic myocardial
wall and embedded in OCTC), stained with DHE (1 mmol/l, dis-
solved in pH 7.4 phosphate buffer solution). A negative control was
obtained by blocking the reaction with N-acetyl-L-cysteine
(100 mmol/l, Sigma-Aldrich).
Both from the stained and the negative control samples 10–15
serial images were captured by a confocal laser scanning micro-
scope (Olympus FV1000). The pictures were acquired using con-
stant microscope setup Objective 40 (Zoom 1.5), Texas Red Fil-
ter, HV448, Gain 3.75, Offset 17%, Scan speed 10 μs (microsecond/
pixel). To avoid a possible difference in the intensity of the back-
ground, a mean value was calculated from 6 control slices to which
each picture was normalised. The intensity of the ﬂuorescent
signals were analysed by ImageJ software (NIH) and expressed in
arbitrary units.2.6. Preparation of simvastatin solution
Before the use of simvastatin (Sigma, St Louis, MO, USA) it
needs to be converted into an active form. A stock solution con-
taining 25 mg simvastatin, dissolved in 625 ml ethanol and 937.5 ml
0.1 N NaOH, was prepared and incubated at 50 °C for 2 h. The pH
of the solution was adjusted to 7.0 with 1 N HCl and stored at
20 °C until use. Immediately prior to the experiments an aliquot
was taken and diluted in distilled water to obtain the appropriate
dose.
2.7. Experimental protocol
Dogs were randomly selected into ﬁve experimental groups
(Fig. 1).1 In each group myocardial ischaemia was induced by a
25 min occlusion of the LAD coronary artery. In the control group
(C; n¼14)1 the solvent of simvastatin (0.5 ml/min), whereas in
another group activated simvastatin (S; n¼12)1 was administered
in a dose of 0.1 mg/kg, in slow (over 5 min) intracoronary injec-
tion, 5 min prior to the onset of the occlusion. In two other groups,
wortmannin alone (W; n¼12, Sigma) or together with simvastatin
(WþS; n¼11) was given in a dose of 1.5 mg/kg also in slow in-
tracoronary injection, 15 min before the administration of the
solvent and simvastatin. Additional 13 dogs were received 0.1%
dimethylsulphoxide (DMSO), the solvent of wortmannin. At the
end of the experiments the hearts were stopped by an excess of
the anaesthetic, and myocardial tissue samples were collected
from the LAD region for further analyses. In at least 5 dogs of each
group, sample taking was performed at the end of the 25 min
occlusion period, whereas in dogs that had been subjected to re-
perfusion, tissue samples were collected either 5 min after re-
perfusion (these animals were considered as survivors) or at the
time when the ﬁbrillation was observed. Eight dogs were used as
sham-operated controls (SC; not included in the protocol ﬁgure).
These dogs were only instrumented, without subjecting them to
any treatment, and from which, after the euthanasia, tissue
G. Kisvári et al. / European Journal of Pharmacology 769 (2015) 185–194188samples were harvested for measuring eNOS phosphorylation and
superoxide production.
2.8. Assessment of the area at risk
The “at risk” area affected by the occlusion was assessed using
the same method that has been described in detail previously
(Végh et al., 1992a). In brief, at the end of the experiments the
heart was removed and Patent Blue V dye was infused into the re-
occluded LAD artery, whereas saline was infused into the patent
left circumﬂex (LCX) artery, at a pressure similar to that the nor-
mal coronary perfusion pressure. The dyed area was cut out and
weighed, and the risk area calculated as a percentage of the left
ventricular wall together with the septum.
2.9. Statistical analysis
The presented values are expressed as the mean7S.E.M. and
the differences between means were compared by ANOVA for
repeated measures and by the one-way ANOVA as appropriate,
using the Fisher post hoc test. VPBs and episodes of VT were
compared using the Kruskal–Wallis test. The incidences of ar-
rhythmias (such as VT and VF) and survival from the combined
ischaemia and reperfusion insult were compared by the Fisher's
exact test. Differences between groups were considered signiﬁcant
at Po0.05.3. Results
3.1. Haemodynamic changes following the administration of solvent,
simvastatin, wortmannin and DMSO, as well as after coronary artery
occlusion
These data are summarised in Tables 1 and 2. There were no
signiﬁcant changes in the haemodynamic parameters following
the local intracoronary injection of simvastatin and wortmannin,
as well as of the vehicle of these drugs (Table 1). Although oc-
clusion of the LAD resulted in signiﬁcant reductions in arterial
blood pressure, LVSP, positive and negative dP/dtmax, and an in-
crease in LVEDP in all groups, these changes were not substantially
different among the groups. The compensatory blood ﬂow chan-
ges, occurring on the LCX when the LAD is occluded, were not
signiﬁcantly modiﬁed by any drug treatment. Furthermore, in
anaesthetised dogs HR was unchanged during coronary artery
occlusion in all groups (Table 2).
3.2. The severity of ventricular arrhythmias during a 25 minTable 1
Haemodynamic changes following solvent, wortmannin, DMSO and simvastatin admini
Solvent Wortmannin
Baseline Change Baseline C
SABP (mm Hg) 14377 372 13174
DABP (mm Hg) 10575 074 9673
MABP (mm Hg) 11875 173 10973
LVSP (mm Hg) 15477 272 13974
LVEDP (mm Hg) 4.370.6 0.570.3 4.070.5
þdP/dt (mm Hg/s) 23517184 90750 21867160 
dP/dt (mm Hg/s) 22667213 40781 24437159
HR (beats/min) 16377 472 15675
mean CBFLCX (ml/min) 4275 172 2573
Data are means7S.E.M. calculated from n¼11–14 experiments. Data, presented as chan
DMSO and simvastatin. SABP, systolic arterial blood pressure; DABP, diastolic arterial b
pressure; LVEDP, left ventricular end-diastolic pressure; HR, heart rate; CBF, coronary bocclusion of the LAD
This is illustrated in Fig. 2. In control dogs occlusion of the LAD
resulted in high number of VPBs (310745) and episodes of VT
(7.171.4) that occurred in 93%of the dogs. Furthermore, 50% of
these control dogs ﬁbrillated during the occlusion and all the re-
maining animals died on reperfusion, thus there were no survivors
in this group from the combined ischaemia and reperfusion insult.
In contrast, the administration of simvastatin markedly reduced
the number of ectopic beats (62714) and episodes of VT
(0.370.2), the incidences of VT (17%) and VF (0%) during occlu-
sion, and 67% of the animals survived reperfusion. These effects of
simvastatin on arrhythmia events were similar to those observed
previously (Kisvári et al., 2014). The administration of wortmannin
in the simvastatin treated dogs signiﬁcantly reduced the antiar-
rhythmic effects of simvastatin. Thus in the presence of wort-
mannin the number of VPBs (307759), the incidence (73%) and
number of episodes of VT (4.371.3) were again increased, and as
with the controls (C and DMSO groups), no dog in the WþS group
survived reperfusion. However, wortmannin did not modify the
effect of simvastatin on the ischaemia-induced VF; i.e. as with
simvastatin alone, no dog in the WþS group ﬁbrillated during the
occlusion period. It is interesting to note that these results accords
with those obtained from studies in which the NOS inhibitor
L-NAME was given in the simvastatin treated animals (Kisvári
et al., 2014). Compared to the controls (C), neither wortmannin,
nor DMSO, the vehicle of wortmannin, affected signiﬁcantly the
severity of arrhythmias resulted from a 25 min occlusion and re-
perfusion of the LAD. Thus in these groups the number of VPBs
was 202764 and 246736, respectively, further 67% and 69% of
these dogs exhibited 3.871.7 and 3.871.6 episodes of VT, and
25% and 23% of the animals ﬁbrillated during the occlusion. In
both groups none of the dogs survived reperfusion.
3.3. Changes in ischaemia severity during a 25 min occlusion of the
LAD
This was assessed by two parameters; changes in the epicardial
ST-segment (Fig. 3A) and in the degree of inhomogeneity of elec-
trical activation (Fig. 3B). In the control groups (C and DMSO) there
were marked increases in both epicardial ST-segment and the
degree of inhomogeneity over the entire occlusion period. Sim-
vastatin markedly suppressed these indices of ischaemia severity,
which effect was completely abolished by the prior administration
of wortmannin. Inhibition of the PI 3-kinase/Akt pathway by
wortmannin did not signiﬁcantly inﬂuence the ischaemia-induced
inhomogeneity and ST-segment changes.stration.
DMSO Simvastatin
hange Baseline Change Baseline Change
072 13576 272 15177 472
072 9375 071 10374 272
072 10875 071 11975 471
172 14675 072 16377 172
0.570.5 3.370.4 0.170.2 5.370.4 070.2
75743 23987116 61755 27877180 79798
57112 26767181 65771 25067216 28750
371 15674 171 16975 371
372 2874 171 3278 172
ges, were determined 5 min after starting the infusion of the solvent, wortmannin,
lood pressure; MABP, mean arterial blood pressure; LVSP, left ventricular systolic
lood ﬂow.
Table 2
Haemodynamic changes during a 25 min occlusion of the LAD.
Control Wortmannin DMSO Simvastatin Wortmanninþsimvastatin
Baseline Max. change Baseline Max. change Baseline Max. change Baseline Max. change Baseline Max. change
SABP (mm Hg) 14677 1072a 13575 1172a 13777 1172a 14875 1172a 15578 1072a
DABP (mm Hg) 10575 1073a 9974 871a 9376 972a 10173 772a 11677 772a
MABP (mm Hg) 11975 1073a 11174 972a 10876 1072a 11774 872a 12977 872a
LVSP (mm Hg) 14679 1072a 14876 1072a 15077 1572a 15277 1172a 16478 1172a
LVEDP (mm Hg) 4.570.6 9.371.3a 4.470.6 9.671.0a 3.470.5 13.271.0a 5.270.3 9.070.9a 4.570.6 9.671.1a
þdP/dt (mm Hg/s) 23107157 495781a 21437161 346766a 25867155 5347109a 26737135 4957114a 24117181 358793a
dP/dt (mm Hg/s) 23167200 4257139a 24467215 540782a 26567210 6247111a 25637183 504791a 25187159 4267113a
HR (beats/min) 16677 474 15477 172 16275 372 16774 472 16275 472
mean CBFLCX (ml/min) 4175 1372 2673 1374 3073 1172 3272 1071 3976 1272
Data are means 7S.E.M. calculated from n¼11–14 experiments.
SABP, systolic arterial blood pressure; DABP, diastolic arterial blood pressure; MABP, mean arterial blood pressure; LVSP, left ventricular systolic pressure; LVEDP, left
ventricular end-diastolic pressure; HR, heart rate; CBF, coronary blood ﬂow.
a Po0.05 compared to baseline value.
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Fig. 2. The number and incidence of ventricular arrhythmias during a 25 min occlusion and reperfusion of the LAD in control (C) and simvastatin (S) treated dogs, as well as
in dogs in which DMSO and wortmannin (W) was given alone or together with simvastatin (WþS). Compared to the controls, simvastatin markedly reduced the numbers of
ventricular premature beats (VPBs) and episodes of ventricular tachycardia (VT), the incidences of VT and ventricular ﬁbrillation (VF) during occlusion and increased survival
from the combined ischaemia and reperfusion insult. These effects, except for the protection against the occlusion-induced VF, were abolished in the presence of wort-
mannin. Neither wortmannin, nor DMSO alone inﬂuenced arrhythmia severity during occlusion and reperfusion. Values are means7S.E.M. *Po0.05 compared to the
controls.
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Compared to the sham operated controls (instrumented but not
subjected to ischaemia; SC), in dogs, infused either with the sol-
vent of simvastatin (C) or with DMSO and subjected to occlusion,
there was a signiﬁcant decrease in eNOS phosphorylation (Fig. 4A).
The administration of simvastatin preserved, and what is more,
slightly increased the activity of eNOS during coronary artery oc-
clusion. This effect of simvastatin on eNOS phosphorylation was
abolished in the presence of wortmannin (WþS group), although
wortmannin (W group) alone did not affect the ischaemia-induced
changes in NOS phosphorylation.
The activation of eNOS through phosphorylation was also de-
termined in dogs that had been subjected to reperfusion (Fig. 4B).
Although these data were collected at different times of the re-
perfusion (according to the occurrence of VF within the 5 min
observation period), the results show that NOS can rapidly regain
its activity, when the coronary artery was suddenly reopened.
Thus following reperfusion the phosphorylation of eNOS was in-
creased in almost all groups, except those that had been received
wortmannin (W and WþS groups) prior to the 25 min occlusionand reperfusion of the LAD.
3.5. Changes in NOx levels during coronary artery occlusion and
reperfusion
These are illustrated in Fig. 5. In control dogs occlusion of the
LAD resulted in a transient, but signiﬁcant increase in NOx (peaked
around 7 min of the occlusion), followed by a continuous decrease
up to the end of the 25 min occlusion period. This ischaemia-in-
duced reduction in NOx was prevented by the application of a
single dose of simvastatin. The administration of wortmannin in
control dogs abolished the early increase of NO metabolites, and it
completely abrogated the NO preserving effect of simvastatin over
the entire occlusion period. DMSO had no effect on NO bioavail-
ability during occlusion and reperfusion.
3.6. Changes in myocardial superoxide production following
reperfusion
In dogs that underwent reperfusion myocardial superoxide
production was determined within a 5 min time interval,
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Fig. 3. Changes in epicardial ST-segment (A) and in the degree of inhomogeneity of
electrical activation (B) during a 25 min occlusion of the LAD. Compared with
controls, simvastatin signiﬁcantly attenuated both indices of ischaemia severity.
These effects of simvastatin were reversed by wortmannin. Neither wortmannin,
nor the solvent of wortmannin (DMSO) affected the ischaemia severity, resulting
from the occlusion of the LAD. Values are means7S.E.M. *Po0.05 compared to the
controls.
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illustrated in Fig. 6. Compared to the sham controls, in dogs sub-
jected to occlusion and reperfusion, there was a marked increase
in superoxide production, which was signiﬁcantly suppressed by
simvastatin. The administration of DMSO, as well as of wortman-
nin itself, did not affect the ischaemia/reperfusion-induced gen-
eration of superoxide, but wortmannin reversed the effect of
simvastatin on superoxide production.3.7. Changes in QTc interval following coronary artery occlusion
As we have previously described, simvastatin prevents the
ischaemia-induced prolongation of the QTc interval, indicating a
possible direct electrophysiological effect of the drug (Kisvári et al.,
2014). The present results conﬁrm these previous ﬁndings,
showing that in the presence of wortmannin the effect of sim-
vastatin on the QTc interval is still maintained (Fig. 7).3.8. Area at risk
There were no signiﬁcant differences in the area at risk among
the groups. Thus the risk area was 3773% in the controls, 3872%
in the simvastatin, 3972% in the wortmannin, 3772% in the
wortmanninþsimvastatin and 3973% in the DMSO groups.4. Discussion
We have shown in the previous study that a single dose of
simvastatin, applying prior to a 25 min period of coronary artery
occlusion in anaesthetised dogs, results in profound protection
against those severe ventricular arrhythmias that are, in most in-
stances, responsible for sudden cardiac death (Kisvári et al., 2014).
We have also pointed out that this antiarrhythmic effect of sim-
vastatin, at least in part, is mediated through nitric oxide, resulting
from an increased activation of endothelial nitric oxide synthase
(eNOS) by simvastatin. The evidence for this comes from the ob-
servation that the inhibition of NOS by L-NAME attenuated the
protective effect of simvastatin against most of the arrhythmia
types that resulted from the sudden occlusion and reperfusion of
one of the main branches of the left coronary artery. The only
arrhythmia event, which was not modiﬁed by L-NAME, was the
incidence of the occlusion-induced VF. Simvastatin markedly
suppressed the occurrence of VF during occlusion, and this effect
was apparent, irrespective whether L-NAME was present or not.
This ﬁnding suggested that in the antiﬁbrillatory effect of sim-
vastatin not only the activation of eNOS, but other mechanisms,
perhaps direct electrophysiological effects of the drug, may also
play a role (Kisvári et al., 2014). This assumption was supported by
the result that L-NAME did not modify the QTc interval reducing
effect of simvastatin (Kisvári et al., 2014). The exploration of the
possible direct electrophysiological effects of the acute simvastatin
treatment warrants further investigations, using more speciﬁc
methods (e.g. cellular electrophysiology), than our in vivo canine
model. Therefore, in the present study we focused on the NO-
mediated effects of simvastatin, and aimed to investigate further
those mechanisms, which participate in the rapid activation of
NOS and the subsequent increase in NO bioavailability.
There are studies in the literature, which showed that statins
can rapidly activate eNOS by stimulating the phoshatidylinositide
3-kinase/Akt (PI 3-kinase/Akt) pathway (Bell and Yellon, 2003;
Wolfrum et al., 2004). For example, in the study of Wolfrum and
colleagues (2004), simvastatin given in anaesthetised rats 3 min
prior to reperfusion markedly reduced infarct size that resulted
from a 30 min coronary artery occlusion and a subsequent 180 min
period of reperfusion. They also showed that simvastatin increased
myocardial PI 3-kinase activity, and enhanced AktSer473 and
eNOSSer1177 phosphorylation. Since the infarct size reducing effect
of simvastatin was abolished by the administration of the PI
3-kinase inhibitor wortmannin and of the NOS inhibitor L-NAME,
they concluded that the activation of PI 3-kinase/Akt/eNOS cas-
cade plays an important role in the acute cardioprotective effects
of simvastatin (Wolfrum et al., 2004).
Starting from this prior observation, we designed studies to
examine whether in our canine model the activation of the PI
3-kinase/Akt/eNOS pathway plays also a role in the antiarrhythmic
effect of the acute simvastatin treatment. We used wortmannin, a
potent and speciﬁc inhibitor of PI 3-kinase, and administered in
dogs prior to the bolus injection of simvastatin. We have found
that in the presence of wortmannin most of the salutary effects of
simvastatin were attenuated, or even abolished. Thus the number
of VPBs, the number of episodes of VT and the incidence of VT
during occlusion were again increased, and compared with the
simvastatin treated group, in which 40% of the dogs survived re-
perfusion, in the wortmanninþsimvastatin group (WþS) no ani-
mal survived the combined ischaemia and reperfusion insult.
However, wortmannin did not inﬂuence the suppressing effect of
simvastatin on the occlusion-induced ventricular ﬁbrillation. Thus,
the marked antiﬁbrillatory effect of simvastatin was still present in
dogs co-treated with the PI 3-kinase inhibitor wortmannin. Fur-
thermore, wortmannin did not affect the QTc interval reducing
effect of simvastatin (Fig. 7). These ﬁndings are very similar to that
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Fig. 4. Changes in the phosphorylated eNOS content, determined by Western blot at the end of the coronary artery occlusion, and 5 min after reperfusion in myocardial
samples taken from control (C) and simvastatin (S) treated dogs, as well as from those dogs that were given DMSO or wortmannin (W) either alone or together with
simvastatin (WþS). Compared to a group of sham-operated dogs (SC, n¼8), occlusion of the LAD for 25 min, resulted in marked decrease in eNOS phosphorylation. This
reduction in eNOS activity was prevented by the administration of simvastatin. Compared with controls DMSO and wortmannin itself did not substantially modify eNOS
phosphorylation, but wortmannin abrogated the simvastatin-induced enhanced phosphorylation of eNOS. Simvastatin resulted in a further increase in eNOS phosphor-
ylation during reperfusion, which effect was also inhibited by wortmannin. Values are means7S.E.M. *Po0.05 compared to the SC group, #Po0.05 compared to the
ischaemic control (C) group, and †Po0.05 compared to the simvastatin group.
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L-NAME, which also abolished the protective effect of simvastatin
against most of the arrhythmia types, except the reduction in the
occlusion-induced VF (Kisvári et al., 2014). Thus the present results
conﬁrm our previous supposition that simvastatin may possesses
with other, NO-independent effect(s), which do not involve the
activation of the PI 3-kinase/Akt/eNOS cascade, but which underischaemic conditions would inﬂuence the occurrence of VF by
directly modifying mechanisms, such as cardiac excitability, re-
polarization, impulse conduction, etc., which are involved in the
generation of VF. These possible direct electrophysiological me-
chanisms have already been discussed in details previously (Kis-
vári et al., 2014), and there is no worth to repeat them here again.
Nevertheless, we are convinced that the NO-mediated
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This was in contrast with the simvastatin treated dogs, where the NOx levels were
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wortmannin the early elevation of NOx in the control dogs, and the enhanced NO
formation in the simvastatin treated dogs were completely abolished, whereas
neither wortmannin, nor DMSO given alone modiﬁed the production of NO me-
tabolites. Reperfusion caused almost similar increases of NOx in all groups. Values
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fects of simvastatin, and that the increased NO production fol-
lowing simvastatin treatment results from the rapid activation of
eNOS, via the stimulation of the upstream PI 3-kinase/Akt path-
way. The evidence for this is that wortmannin, similar to L-NAME
(Kisvári et al., 2014), completely abolished the reducing effect of
simvastatin on the indices of ischaemia severity, such as theS
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Fig. 6. Tissue superoxide production following a 25 min occlusion and reperfusion of
(S) treated dogs. The ﬁgure also shows the effects of DMSO and wortmannin alone (W)
increase in superoxide production in dogs subjected to a 25 min occlusion/reperfusion in
wortmannin given alone did not modify the production of superoxide, but wortmannin
*Po0.05 compared to the SC group and #Po0.05 compared to the control (C) group.epicardial ST-segment and the degree of inhomogeneity of elec-
trical activation (Fig. 3). Also, in the presence of wortmannin, the
increased NO production that resulted from simvastatin adminis-
tration, was again reduced (Fig. 5). It is interesting to note that
both L-NAME and wortmannin abolished the transient elevation of
NO formation, which was apparent even in the control dogs soon
after the commencement of the coronary artery occlusion. This
ﬁnding suggests three things. First, a short period of ischaemia
(e.g. 5 min), rapidly activates NOS and results in enhanced NO
formation. However, this increase in NO bioavailability is transient,
if the ischaemia is maintained over a longer period (e.g. 25 min),
then the activity of NOS, and consequently, the NO production, are60 µm C
DMSO
W+S
the LAD in sham-operated (SC) and in ischaemic controls (C) and in simvastatin
or together with simvastatin (WþS). Compared to the SC dogs, there was a marked
sult, which was markedly reduced by the administration of simvastatin. DMSO and
abolished the superoxide reducing effect of simvastatin. Values are means7S.E.M.
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short period of ischaemic insult (e.g. preconditioning, Juhász et al.,
2014), rapidly activates NOS, but in this case the enzyme remains
to be activated even during a longer period of occlusion, resulting
in increased levels of NOx throughout the prolonged ischaemic
insult (Kisvári et al., 2014; Juhász et al., 2014). Thirdly, the acti-
vation of NOS, resulting from both the application of simvastatin
and a preconditioning stimulus, can be blocked by L-NAME (Végh
et al., 1992b; Wolfrum et al., 2004; Kisvári et al., 2014), and also by
wortmannin (Tong et al., 2000; Wolfrum et al., 2004). This sug-
gests that there might be a common pathway in NOS activation
both by simvastatin and preconditioning. Indeed, there is evidence
coming mainly from in vitro experiments that phosphorylation of
NOS rapidly modiﬁes NOS activity (Mount et al., 2007). For ex-
ample, it has been recently reported that in the rat isolated hearts,
preconditioning, by stimulating the Akt/protein kinase A (PKA)
pathway, activates eNOS via serine 1176 phosphorylation (Yang
et al., 2013). There is also evidence that the PI 3-kinase inhibitor
wortmannin abolished the preconditioning-induced phosphor-
ylation of protein kinase B (Akt) and the increase in NO production
in Langendorff-perfused rat hearts (Tong et al., 2000).
In our present experiments, similar to that observed in the
study of Wolfrum and colleagues (2004), wortmannin completely
blocked the simvastatin-induced phosphorylation of eNOS (Fig. 4)
and inhibited NO formation (Fig. 5) during the entire 25 min
period of occlusion. We are convinced that NO bioavailability
during occlusion plays an essential role in arrhythmia generation
both during occlusion and reperfusion (Végh et al., 1992b; Kiss
et al., 2010; Gönczi et al., 2009; Juhász et al., 2014; Kisvári et al.,
2014). Thus any manoeuvre, which increases or, at least, maintains
NO formation during occlusion may protect the myocardium
against arrhythmias, most probably through the regulation of
those local and systemic mechanisms by NO that are implicated in
arrhythmia generation, such as the autonomic tone (Schwartz
et al., 1995), gap junctional function (Gönczi et al., 2009; Végh
et al., 2013), or the formation of free radicals (e.g. Iwase et al.,
2007; Kiss et al., 2010), etc. The latter is particularly important in
the generation of the reperfusion-induced severe ventricular ar-
rhythmias, and NO by reducing free radical formation (most likely
superoxide) may suppress the occurrence of arrhythmias during
reperfusion (Kiss et al., 2010). Since both L-NAME (Kisvári et al.,
2014) and, as the present study showed, wortmannin abolished
the suppressing effect of simvastatin on the reperfusion-induced
superoxide production and subsequently increased the incidence
of VF during reperfusion, it seems more than likely that this effect
of simvastatin is NO-dependent and it attains via the activation of
the PI 3-kinase/Akt/eNOS pathway.
Although these experiments were carefully designed, and
performed under controlled conditions, there are some limitations
of the present study that worth to be mentioned. First, in this
series of experiments the collateral blood ﬂow was not measured.
We have previous evidence that in this arrhythmia model, the use
of microspheres during the vulnerable, early (25 min) period of
ischaemia can substantially modify arrhythmia severity (Babai
et al., 2002). Therefore, we do not attempt to assess tissue blood
ﬂow in all of our studies, when the arrhythmias are assessed.
However, we assessed the size of that area, which was affected by
the occlusion in order to verify similar risk areas in dogs, involved
in the various groups. The changes in the severity of ischaemia
(epicardial ST-segment, degree of inhomogeneity of electrical ac-
tivation) over the entire occlusion period were also assessed.
Second, we have no direct evidence as to whether the applied dose
of wortmannin completely inhibits PI 3-kinase, since in the pre-
sent study the activity of this enzyme was not determined. At the
selection of the dose of wortmannin, we were relied on the data of
Wolfrum et al. (2004), who measured PI 3-kinase activity, albeit ina different model. Nevertheless, in this study the intracoronary
administration of wortmannin in a dose of 1.5 mg/kg, completely
abolished all the examined effects of simvastatin, except the re-
duction in the occlusion-induced ventricular ﬁbrillation and in QTc
interval that were apparent in dogs treated with simvastatin, no
matter whether wortmannin was present or not. These present
and our previous (Kisvári et al., 2014) ﬁndings led us to propose
that in the antiarrhythmic (antiﬁbrillatory) effect of simvastatin a
direct and perhaps NO-independent mechanism may also play a
role.
In summary, the present study demonstrates that the antiar-
rhythmic effect of simvastatin is largely depends on the formation
of NO that results from the rapid activation of eNOS via the sti-
mulation of the PI 3-kinase/Akt pathway. The evidence for this is
that most of the salutary effects of simvastatin (except the pro-
tection against the occlusion-induced VF) are attenuated or even
abolished, if PI 3-kinase, one of the upstream components of NOS
activation is inhibited with wortmannin. Thus we think that the
activation of PI 3-kinase/Akt/eNOS cascade and the subsequent
increased formation of NO play a crucial role in the antiarrhythmic
effect of acute simvastatin administration, but a direct and pre-
sumably NO-independent mechanism cannot also be ruled out.Acknowledgements
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